Mouse bioassay versus Western blot assay for botulinum toxin antibodies: Correlation with clinical response

Neurology

Volumn 50, Issue 6, 1998, Pages 1624-1629

  Hanna, Philip A ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BIOASSAY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DYSTONIA; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031776446     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1624     Document Type: Article

References (27)

1. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
2. Jankovic J. Use of botulinum toxin in neurology. In: Kennard C, ed. Recent advances in clinical neurology. Volume 8. Edinburgh: Churchill Livingstone, 1995:89-110.
3. American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurological disorders; report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40:1332-1336.
4. American Academy of Ophthalmology. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. Ophthalmology 1989;96(suppl):37-41.
5. Davidson BJ, Ludlow CL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol 1996;105:33-42.
6. National Institutes of Health. Consensus development conference statement on clinical use of botulinum toxin. Arch Neurol 1991;48:1294-1298.
7. Clarke CE. Therapeutic potential of botulinum toxin in neurologic disorders. Q J Med 1992;82:197-205.
8. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-639.
9. Berardelli A, Formica A, Mercuri B, et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital J Neurol Sci 1993;14:361-367.
10. Geller BD, Hallett M, Ravits J. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiological studies. Muscle Nerve 1989;12:716-722.
11. Scott AB. Foreword. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:vii-viii.
12. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
13. Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993; 100:1861-1866.
14. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 93-107.
15. Notermans S, Dufrenne J, Van Schothorst M. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum toxin type A. Japan J Med Sei Biol 1978;31:81-85.
16. Notermans S, Nagel J. Assays for botulinum and tetanus toxins. In: Simpson LL, ed. Botulinum neurotoxin and tetanus toxin. San Diego: Academic Press, 1989:319-331.
17. Shone C, Wilton-Smith P, Appleton N, et al. Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 1985;50:63-67.
18. Jankovic J, Schwartz KS. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
19. Smith LDS, ed. Botulism: the organism, its toxins, the disease. Springfield IL: Charles C Thomas, 1977.
20. 125I-Bot-A. J Neurol Neurosurg Psychiatry 1996;61:224. Abstract.
21. Kessler KR, Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin A. Mov Disord 1997;12:95-99.
22. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.
23. Moyer E, Settler PE. Botulinum toxin type B: experimental and clinical experience. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 71-86.
24. Borodic GE, Pearce LB, Smith KL, et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993;9:182-190.
25. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992;326:349-350. Letter.
26. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
27. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BR, ed. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press, 1993:651-654.